You are here: Industry Insights > HER2

News List

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS PR Newswire
May 12, 2025
RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) has reached its two primary endpoints of progression-free survival (PFS) and overall survival (OS).
Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis PRNewswire
December 13, 2024
Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
Enhertu bags US priority review for HER2 gastric cancer pharmatimes
October 29, 2020
AstraZeneca’s Enhertu has scored a priority review from the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic gastric cancer.
AZ, Daiichi grab blockbuster nod for breast cancer med Enhertu fiercepharma
December 27, 2019
For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition.
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies worldpharmanews
December 23, 2019
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable ...
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer drugs
December 12, 2019
Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with ...
Drug Combo Slows Progression in Advanced Breast Cancer drugs
June 25, 2019
Drug Combo Slows Progression in Advanced Breast Cancer.
FDA Approves Roche's Kadcyla for HER2-Positive Early Breast Cancer contractpharma
June 14, 2019
An adjuvant treatment for patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer worldpharmanews
May 10, 2019
Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer.
Roche launches HER2 biomarker test for breast and gastric cancer pharmatimes
May 09, 2019
Roche has launched a new assay that can detect the HER2 biomarker in breast and gastric cancer in the UK.